BRIGHT MINDS BIOSCIENCES INC. Schedule 13G discloses that Vestal Point Capital and Ryan Wilder report beneficial ownership of 492,319 shares of Common Shares, representing 5% of the class. The percentage is calculated using 9,787,161 Common Shares outstanding as of February 12, 2026 as stated in the filing. The filing shows shared voting and shared dispositive power over the reported shares and states the shares are held on behalf of the Vestal Point Fund and Account.
Positive
None.
Negative
None.
Insights
Institutional holder reports a 5% stake via shared control.
The filing lists Vestal Point Capital and Mr. Ryan Wilder as reporting persons with 492,319 shares and 5% ownership, calculated from 9,787,161 outstanding shares as of February 12, 2026. This identifies a visible institutional position without asserting sole control.
Watch subsequent filings for changes to voting or dispositive power; any change would be disclosed in amendments to this Schedule 13G.
Shared voting and dispositive power indicates manager-level influence, not unilateral control.
The disclosure shows shared voting power and shared dispositive power of 492,319 shares, and states the shares are held on behalf of the Vestal Point Fund and Account. The filing includes a joint filing agreement signed by Mr. Ryan Wilder.
Corporate actions requiring majority votes are not implied here; the filing documents a reported position and the allocation of authority as disclosed.
Key Figures
Reported shares:492,319 sharesPercent of class:5%Shares outstanding:9,787,161 shares
3 metrics
Reported shares492,319 sharesBeneficial ownership reported by Vestal Point and Ryan Wilder
Percent of class<percent>5%</percent>Percent of Common Shares calculated in filing
Shares outstanding9,787,161 sharesOutstanding as of <date>February 12, 2026</date>
"This statement is filed by: Vestal Point Capital, LP ..."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Shared dispositive powercorporate governance
"Shared Dispositive Power 492,319.00"
Beneficially ownedregulatory
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
BRIGHT MINDS BIOSCIENCES INC.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
10919W405
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
Vestal Point Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
492,319.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
492,319.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
492,319.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
Ryan Wilder
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
492,319.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
492,319.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
492,319.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
BRIGHT MINDS BIOSCIENCES INC.
(b)
Address of issuer's principal executive offices:
1122 Mainland St #228, Vancouver British Columbia V6B 5L1.
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the common, no par value (the "Common Shares"), of BRIGHT MIND BIOSCIENCES INC. (the "Company") directly held by the Vestal Point Fund and Account; and
(ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the Common Shares directly held by the Vestal Point Fund and Account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
(c)
Citizenship:
The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States.
(d)
Title of class of securities:
Common Shares, no par value
(e)
CUSIP Number(s):
10919W405
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 9,787,161 Common Shares outstanding as of February 12, 2026, as reported in the Company's Management Discussion and Analysis attached as Exhibit 99.2 to the Report of Foreign Private Issuer on Form 6-K, filed with the Securities and Exchange Commission on February 13, 2026.
(b)
Percent of class:
5%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vestal Point Capital, LP
Signature:
/s/ Ryan Wilder
Name/Title:
By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
What stake does Vestal Point Capital report in BRIGHT MINDS BIOSCIENCES (DRUG)?
Vestal Point Capital and Ryan Wilder report 492,319 shares, equal to 5% of the class, per the Schedule 13G. The percentage is based on 9,787,161 shares outstanding as of February 12, 2026 shown in the filing.
Does the Schedule 13G show who controls voting of the reported shares?
The filing states the reporting persons have shared voting power and shared dispositive power over the 492,319 shares. It does not claim sole voting or sole dispositive authority in the disclosed rows.
Are the reported shares held personally by Ryan Wilder?
No. The Schedule 13G states the shares are held by the Vestal Point Fund and Account and that Mr. Wilder files as the Investment Manager's managing partner and reports shared power on their behalf.
What outstanding share count does the filing use to calculate the 5% figure?
The filing calculates 5% using an aggregate of 9,787,161 Common Shares outstanding as of February 12, 2026, per the company's Management Discussion and Analysis cited in the filing.
Who signed the Schedule 13G for Vestal Point Capital and Ryan Wilder?
The Schedule 13G was signed by Ryan Wilder both on behalf of Vestal Point Capital, LLC as general partner and in his individual capacity, with signature dates shown as May 15, 2026.
